Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study.
暂无分享,去创建一个
R. Burger | D. Spriggs | H. Gallion | L. Carson | S. Lentz | M. Markman
[1] D. Strumberg,et al. Paclitaxel plus ifosfamide in advanced ovarian cancer: results of a phase I study. , 1998, Anti-cancer drugs.
[2] R. Berkowitz,et al. A phase I trial of ifosfamide and paclitaxel with granulocyte‐colony stimulating factor in the treatment of patients with refractory solid tumors , 1998 .
[3] M. Martini,et al. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study. , 1997, Oncology.
[4] Stefan Mihalas,et al. Ifosfamide and paclitaxel salvage chemotherapy for advanced epithelial ovarian cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] D. Mutch,et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Mutch,et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.
[7] U. Vanhoefer,et al. Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines. , 1996, British Journal of Cancer.
[8] W. Mcguire,et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Partridge,et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.
[10] J B Vermorken,et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Thigpen,et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Rubin,et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Vance,et al. Ifosfamide in the management of gynecologic cancers. , 1990, Seminars in oncology.
[14] G. Sutton,et al. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.